High Frequency and Adverse Impact of Vertigo and Dizziness in Multiple Sclerosis (P07.075)
Bibliographic record
Abstract
Objective: Using the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry data, we examined factors that worsened the level and impact of dizziness or vertigo (DOV) in persons with MS. Background Few prior studies examined the frequency or impact of DOV in MS. Design/Methods: In 2004, registry participants answered questions regarding DOV, including what factors aggravated their symptoms, and how their symptoms influenced their daily activities. Results: 8123 participants completed the questionnaire, of whom 74.5% were women, 96.6% white, and 70.2% married/ co-habiting. Their mean (SD) age of symptom onset was 30.3 (9.7) years and median (IQR) score on Patient Determined Disease Steps (PDDS) was 4 (1-6). Nearly all participants reported at least some difficulty with DOV (N = 8122). DOV frequently worsened with head movement (56.0%), bending over (54.5%) and looking upward (47.5%), but infrequently with turning over in bed (19.4%). As compared to men, women more often reported that looking up (p=0.003), head movement (p Conclusions: Dizziness or vertigo are frequent, limit daily activities, and adversely affect relationships in MS. More effective management is needed. Supported by: NARCOMS is a CMSC project. Disclosure: Dr. Marrie has nothing to disclose. Dr. Cutter has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc., Cleveland Clinic, Daiichi Pharmaceutical Corporation, GlaxoSmithKline, Inc., Genmab Biopharmaceuticals, Eli Lilly & Company, Medivation, Modigenetech, Ono Pharmaceutical, PTC Therapeutics, Teva Neuroscience, Vivus, University of Pennsylvania, NHLBI, NINDS, NMSS, Alexion, Bayhill Therapeutics, Bayer Pharmaceuticals Corporation, Celgene, Novartis, Consortium of MS Centers, Genzyme Corporation, Klein-Buendel Incorporated, Nuron Biotech, Peptimmune, Somnus Pharmaceuticals, Sandoz, University of Texas Southwestern and Visioneering Technologies, Inc. Dr. Cutter has received compensation for serving on the board of Pythagoras, INC. Dr. Cutter has received research support from various pharmaceutical corporations. Dr. Tyry has nothing to disclose.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".